










99.5% PURITY LOT VL-2799-A Retatrutide + PEN
A Triple R supplied as a 5 mg lyophilized vial for advanced metabolic and energy-balance research + Injector Pen
A 10 mg lyophilized vial of the Triple R for advanced metabolic research + Disposable injector PEN
A high-strength 20 mg lyophilized vial of the Triple R for extended metabolic research.
- 1 × Triple R 5mg vial
- 1 × pen
- 1 × 3 mL pen cartridge
- Bacteriostatic water (3 mL)
- 1 × Triple R 10mg vial
- 1 × pen
- 1 × 3 mL pen cartridge
- Bacteriostatic water (3 mL)
- 1 × Triple R 20mg vial
- 1 × pen
- 1 × 3 mL pen cartridge
- Bacteriostatic water (3 mL)
About this compound
A Triple R supplied as a 5 mg lyophilized vial for advanced metabolic and energy-balance research + Injector Pen
- 10 mg lyophilized peptide per vial
- Synthetic peptide, ≥99% purity
- Studied for energy balance and body-weight regulation
A 10 mg lyophilized vial of the Triple R for advanced metabolic research + Disposable injector PEN
- 10 mg lyophilized peptide per vial
- Synthetic peptide, ≥99% purity
- Studied for energy balance and body-weight regulation
A high-strength 20 mg lyophilized vial of the Triple R for extended metabolic research.
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Technical data
Technical data
Current lot snapshot
Shipping
Reported use in research
This 10 mg vial supports research into energy balance, glucose control, and body-weight regulation, where the simultaneous engagement of multiple metabolic pathways is of particular interest for metabolic models.
Reported findings
Phase 2 data show dose-dependent metabolic effects, with the highest doses producing body-weight reductions of roughly 24% over 48 weeks alongside improvements in glycemic and hepatic markers. Intermediate doses such as 10 mg are used to characterize the dose-response relationship.
Handling & safety
Adverse events are predominantly gastrointestinal and dose-dependent. As with other high-potency metabolic research peptides, heart-rate and metabolic monitoring remain relevant in research models. The majority of reported events are mild to moderate.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with — | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 4.99 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with — | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 5.00 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4731.33 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 10.03 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4731.33 g/mol | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 10.04 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4731.33 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 10.03 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with — | PASS |
| Purity | HPLC (area %) | 99.0% | PASS |
| Net peptide content | Gravimetric | 20.04 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with — | PASS |
| Purity | HPLC (area %) | 99.1% | PASS |
| Net peptide content | Gravimetric | 20.02 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with — | PASS |
| Purity | HPLC (area %) | 99.2% | PASS |
| Net peptide content | Gravimetric | 20.00 mg | PASS |
| Appearance | Visual | White to off-white powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2799-A | Jul 2026 | 99.5% | TR-88559 | Active | |
| VL-2780-B | May 2026 | 99.4% | TR-88626 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2943-A | Jul 2026 | 99.5% | TR-88031 | Active | |
| VL-2924-B | May 2026 | 99.4% | TR-88098 | Sold out | |
| VL-2981-C | Mar 2026 | 99.7% | TR-88125 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2768-A | Jul 2026 | 99.0% | TR-88766 | Active | |
| VL-2787-B | May 2026 | 99.1% | TR-88699 | Sold out | |
| VL-2806-C | Mar 2026 | 99.2% | TR-88708 | Sold out |